Gemini Therapeutics (GMTX) Stock Chart & Stock Price History $53.71 +1.00 (+1.90%) As of 06/13/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock Gemini Therapeutics Stock Price Performance The Gemini Therapeutics (GMTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 37.16%, with a year-to-date return of -12.81%. In the past month, the stock has increased 17.45%, reflecting recent market activity. As of the latest close, Gemini Therapeutics traded at $52.71 with a market cap of $2.28 billion and volume of 396,554 shares. Receive GMTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+4.45%1 Month Performance+17.45%3 Month Performance+2.48%Year-To-Date Performance-12.81%1 Year Performance+37.16% GMTX Stock Chart for Sunday, June, 15, 2025 GMTX Chart by TradingView Gemini Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/13/2025$50.86$52.71+3.64%$53.30$49.80396,554 shs$2.28 billion06/12/2025$53.07$50.86-4.16%$53.52$50.85397,276 shs$2.20 billion06/11/2025$51.42$53.07+3.21%$54.28$51.36359,190 shs$2.30 billion06/10/2025$50.02$51.42+2.80%$51.53$49.27639,815 shs$2.23 billion06/09/2025$50.02$50.02$50.15$48.50223,217 shs$2.17 billion06/06/2025$47.32$48.01+1.46%$49.02$46.54412,670 shs$2.08 billion06/05/2025$47.40$47.32-0.17%$48.57$47.17284,914 shs$2.05 billion06/04/2025$47.73$47.40-0.69%$48.94$46.96462,791 shs$2.05 billion06/03/2025$46.68$47.73+2.25%$48.42$46.03439,547 shs$58.49 million06/02/2025$46.68$46.68$47.22$44.47437,325 shs$2.02 billion Get the Latest News and Ratings for GMTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/30/2025$45.12$46.87+3.88%$47.36$44.96337,234 shs$2.03 billion05/29/2025$45.88$45.12-1.66%$47.25$44.85274,276 shs$1.95 billion05/28/2025$47.37$45.88-3.15%$48.83$45.58345,633 shs$1.99 billion05/27/2025$47.37$47.37$47.56$46.80132,011 shs$2.05 billion05/26/2025$47.37$47.37$47.56$46.80132,011 shs$2.05 billion05/23/2025$48.89$48.04-1.74%$49.93$47.91216,877 shs$2.08 billion05/22/2025$50.08$48.89-2.38%$50.12$48.21264,595 shs$2.12 billion05/21/2025$49.69$50.08+0.80%$50.35$48.18310,725 shs$2.17 billion05/20/2025$48.09$49.69+3.32%$49.79$47.26316,155 shs$2.15 billion05/19/2025$48.09$48.09$48.20$46.51442,392 shs$2.08 billion05/16/2025$45.73$47.09+2.97%$47.19$45.19306,342 shs$2.04 billion05/15/2025$46.35$45.73-1.34%$47.45$44.80218,935 shs$1.98 billion05/14/2025$46.61$46.35-0.56%$46.99$44.86273,255 shs$2.01 billion Related Companies Blueprint Medicines Stock Price Chart Roivant Sciences Stock Price Chart Revolution Medicines Stock Price Chart BridgeBio Pharma Stock Price Chart Elanco Animal Health Stock Price Chart Verona Pharma Stock Price Chart Legend Biotech Stock Price Chart TG Therapeutics Stock Price Chart Grifols Stock Price Chart Lantheus Stock Price Chart Receive GMTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GMTX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
